«ÊËÈÍÈ×ÅÑÊÎÅ ÇÍÀ×ÅÍÈÅ ÌÀÐÊÅÐΠÊÎÑÒÍÎÃÎ ÌÅÒÀÁÎËÈÇÌÀ Ó ÁÎËÜÍÛÕ ÐÀÊÎÌ ÌÎËÎ×ÍÎÉ ÆÅËÅÇÛ ...»
Kaufinann, G. Bastert // Berlin, Springer-Verlag. –1994. – P. 186.
56.Predictors of skeletal complications in patients with metastatic breast carcinoma / S.M. Domchek, J.Younger, D.M. Finkelstein et al. // Cancer. –2000. – Vol. 89, ¹2. – P. 363-368.
57.Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review meta-analysis / W.X.
Du, S.F. Duan, J.J. Chen et al. // J. Cancer Res Ther. –2014. – Vol.10. Supp 2. – P.140-143.
58.Ebert W. Comparison of bone scintigraphy with in the diagnosis of bone metastasis in lung carcinoma patients /W. Ebert, T. Muley, K. Herb, H. Schmidt – Gayk//. Anticancer Res. -2004. -Vol.24, ¹5/ – P. 3193- 3201.
59.Eriksen, E.F. The cellular basis of bone remodeling / E.F. Eriksen, M. Kassem // Triangle. – 1992. – Vol.31. –P.45 -57.
60.Positron emission tomography and bone metastases /I. Fogelman, G. Cook, O.
Istrael et al. // Semin Nucl Med. – 2005. – Vol.35. – P.135-142.
61.Diagnostic accuracy of bone metastasis detection in cancer patients: comparison between bone scintigraphy and whole – body FDG – PET / R. Fujimoto, T.
Higashi, Y. Nakamoto et al. // Annals of Nuclear Medicine. – 2006. – Vol.26, ¹6. – P 399-408.
62.Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as a serum marker of bone metastases in human breast cancer/ B. Capeller, H.Caffier, M.W. Sutterlin et al.//Anticancer Res. – 2003. –Vol. 23, ¹ 2A. – P. 1011-1015.
63.Galasko, C. S. Diagnosis of skeletal metastases and assessment of response to treatment / Metastatic Bone Disease: Fundamental and Clinical Aspects Springer Verlag Berlin Heidelberg.–1994. –P. 93-108.
64.Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in in breast cancer patients with bone metastases/ D. Generali, A.Dovio, M. Tampellini et al. // British J of Cancer. – 2008. –Vol. 98. – P. 1753- 1758.
65.Cytokines as markers of osteolysis in the diagnostics of patients with bone metastases / M. Groblewska, B. Mroczko, M. Czygier, M. Szmitkowski // Bialystok. –2008. – Vol. 62..–P. 668-675.
66.Prospective evaluation of the peptide – bound collagen type ² cross – linked Ntelopeptide and C – telopeptide in predicting bone metastases status / L. Gosta, L.M. Demers, A. Gouneia – Oliveirsa at al. //J. Clin Oncol. – 2002. – Vol. 20. – P. 850 - 856.
67.Gremers, S. Bone markers/ S. Gremers, J. P. Bilezikian, P Garnero // New Aspects. Clin. Lab. –2008. – Vol. 54 – P.461 - 471.
68.Tartrate – resistant acid phosphatase 5b (TRACP) as a marker of bone resorption / J.M. Hallen, S.L. Titinen, H.Ylipahkala at al. //Clin Lab.–2006. – Vol. 52. – P.499 – 509.
69.Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity / V. Hirsh, P.P Major and A.
Lipton at al. // J Thorac Oncol. –2008. – Vol. 3. – P. 228-236.
70.Increased tartrate-resistant acid phosphatase (TRAP) 5b expression in malignant breast, ovarian and melanoma tissue: an investigational study/ A. Honig, L.
Rieger, M. Kapp et al. //BMC Cancer. – 2006. –Vol. 6. – P. 199.
71.Huang, Q. Biochemical-markers for the diagnosis of bone metastases: a clinical review /. Q. Huang, X. Quyang // Cancer Epidemiology. – 2012. –Vol. 36. –P.
94-98.
72.Hung, M.J. Value of TRAcP 5b as a diagnostic marker for detection of bone metastases in patients with breast cancer / M.J. Hung, G.M. Oremek // Eur J Gynaecol Oncol. – 2011. – Vol. 32, ¹ 6. – P.615-618.
73.Diagnostic value of bone- turnover metabolites in the diagnosis of bone metastasis in patients with lung carcinoma/ M. Izumi, Y. Takayama, K.
Kimotsuki et al.// Cancer. – 2001. – Vol. 91, ¹8. – P.1487-1493.
74.Jung, K. Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers metastasis / K. Jung, M. Lein // Biochim Biophys Acta. – 2014. – Vol. 1846, ¹2. – P.425 - 438.
75.A multigenis program mediating breast cancer metastasis to bone /Y. Kang, P. M, W. Shu at al // Cancer Cell. – 2003. – Vol.3. – P.537-549.
76.A high incidence of vertebral fracture in women with breast cancer/ J.A. Kanis, E.V. McCloskey, T. Powles at al. //British Journal of Cancer. – 1999. – Vol. 79. – P.1179 - 1181.
77.Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer / Q.Q. Kong, T.W. Sun, Q.Y. Dou at al //- Int J Biol Markers. – 2007. – Vol. 22, ¹ 3. – P 214-220.
78.Diagnosis of vertebral metastasis, epidural metastasis, and malignant spinal cord compression: are T(1)-weighted sagittal images sufficient? / J.K. Kim, T.J.
Learch, P.M. Colletti et al. // Magn Reson Imaging. – 2000. – Vol. 18, ¹ 7. – P.
819-824.
79.Kominsky, S.L. A"bone" fide predictor of metastases? Predicting breast cancer metastases to the bone / S.L. Kominsky, N.E.Davidson //J Clin Oncol. – 2006. – Vol. 24. – P. 2227 - 2229.
80.Diagnostic bone scanning in oncology/ A.Z. Krasnow, R.S. Hellman, M.E.
Tiwiins et al //Semin Nuc Med. –1997. –Vol. 27. – P. 107- 141.
81.Osteocalcin and other serum markers of bone metabolism in a healthy population / V. Kusec, M. Kramaric, I. Baric at al. / Clin Lab. – 1998. – V. 44. – P. 277-283.
82.Alpha CTX as a biomarker of skeletal invasion of breast cancer:
immunolocalization and the load dependency of urinary excretion / D. J.
Leeming, G. Delling, M. Koizumi et al. // Ñancer Epidemiol. Biomarkers Prev. – 2006. –Vol.15, ¹7. – P. 1392-1395.
83.Relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients / D. J. Leeming, M.
Koizumi, I. Byrjalsen at al. //Cancer Epidemiol. Biomarkers Prev. –2006. – Vol.15, ¹1. – P. 32-38.
84.Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic àcid for detection of bone metastases progression / M. Lein, M.
Wirth, K. Miller at al. // Eur Urol. –2007. –Vol.52, ¹5. – P.1381-1387.
85.Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases/ S.F. Li, X.R.
Wang, C. Wang at al. // Zhonghua Zhong Liu Za Zhi. – 2009. – Vol.31, ¹ 12. – P. 911- 915.
86.Modeling the interactinos between osteolast and osteoblast activities in bone remodelling / V. Lemaire, F.L.Tobin, L.D. Greller at al. / J. Theor Biol. –2004. – Vol. 229, ¹3. – P. 293 -309.
87.Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity / A. Lipton, R.J. Cook, P. Major at al // Oncologist. – 2007. – Vol. 12. – P. 1035 – 1043.
88.Systemic Therapy for Bone Metastasis / L.S. Loftus, S. Edwards-Bennett, G. H.
Sokol at al. // Cancer Control. – 2012. –Vol. 19, ¹2. – P. 145 - 153.
89.Lpez-Carrizosa M.C. Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases/ M.C.
Lpez-Carrizosa, P.M. Samper-Ots, A.R. Prez //Clin. Transl. Oncol. 2010. –Vol 12, ¹8.
90.Normalization of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer/ D.R. Luftner, A. Richter, R.
Geppert et al. //Anticancer Res. – 2003. – Vol.23, ¹2A. – P.1017-1026.
91.Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases / F. Lumachi, F. Marino, G.Fanti at al. // Preliminary results Anticancer Res. – 2011. – Vol.31, ¹11. – P. 3879 - 3881.
92.Maeda, H. Correlation between bone metabolic markers and bone scan in prostatic cancer / H. Maeda, M. Koizum K. Yoshimura J. // Urol. – 1997 – Vol.
157. – P. 539-543.
93.Brief courses of palliative radiotherapy for metastatic bone pain: a pilot costminimization comparison with, narcotic analgesics / R.M. Macklis, H. Cornelli, J.
Lasher // Am J Clin Oncol. –1998. –Vol.21, ¹6. – P.617-622.
94.Malaver, M. Treatment of metastatic bone disease / M. Malaver // In.:
Musculoskeletal cancer surgery. –2001. – P. 216-230.
95.Relative contribution of bone density? Bone turnover and clinical risk factors to long – term fracture prediction / L.J. Melton, S.C. Growson, W.M.OFallon at al.
// J Bone Miner Res. –2003. – Vol.18. – P.312-318.
96.Morony, S. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis cancer research / S. Morony, C. Capparelli, S. Sarosi //. – 2001. – Vol. 61 –. P.
4432-4436.
97.Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data/ G. Mountzios, V. Ramfidis, E. Terpos, K.N. Syrigos /Clinical lung cancer. – 2011. – Vol. 12, ¹6. – P.341-349.
98.Mundy, G.R. Mechanisms of osteolytic bone destruction / G.R. Mundy, B. F.
Boyce and T. Yoneda // In: Metastatic Bone Disease: Fundamental and Clinical Aspects. – Heidelberg. – 1994. – P. 86 - 92.
99.Mundy, G.R. Metastasis to bone: causes, conseguences and therapeutic opportunities/ G.R. Mundy //Nat. Rev. Cancer. – 2002. –Vol. 2, ¹ 8. – P. 584 Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications/ E.C. Nelson, C. P. Evans, C.X. Pan at al. // World J Urol. – 2007. –Vol. 25. – P. 393-399.
101. Nguyen, T. Variability in the measurement of biochemical markers of bone turnover. In: M.J. Seibel, S.P. Robins. J.P. Bilezikian (eds) Dynamics of bone and cartilage metabolism / T. Nguyen, C. Meier, C. Seibel // 2 Edition; Academic Press, San Diego. – 2006.
102. Newman, L.A. Evidence-based management of breast cancer/ L.A.
Newman, D.F. Hayes // In: Oncology. An credence –based approach. – New York: pringer. –2006.
103. Papacbristou, D.J. Bone metastases: moleñular mechanisms and therapeutic interventions/ D.J. Papacbristou, E.K. Basdra, A.G. Papavassiliou // Med Res Rev. – 2012. – Vol.32, ¹3. –P. 611- 636.
104. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid/ D. Pectasides, M. Nikolaou, D. Farmakis et al. //Anticancer Res. –2005. –Vol. 25. – P. 1457-63.
105. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer / D. Pectasides, D. Farmakis, M.
Nirolaou at al // Pharm Biomed Anal. – 2005. –Vol.37, ¹1. –P 171-176.
106. Piccart, M.J. Integration of new therapies into management of metastatic breast cancer / M. J Piccart, A. Awada, A. Hamiton // ASCO Educational book. – Atlanta. – 1999. – P.526 - 539.
107. Plunkett, T.A. Risk of complications from bone metastases in breast cancer, implications for management / T.A. Plunkett, P. Smith, R.D. Rubens // Eur J Cancer. – 2000. – Vol.36, ¹4. – P. 476-482.
108. New and traditional serum markers of bone metabolism in the detection of skeletal metastases/ M. Plebani, D. Bernardi, M.Zaninotto at al // Clin Biochem 29. – 1996. – P. 67-72.
Circadian variation in serum concentration of C – terminal telopeptide of 109.
type ² collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting / P. Qvisit, S.Ñhristgau, B.J. Pedersen at al // Bone. –2002. – Vol. 31, ¹1. – P. 57- 61.
110. Zoledroniñ acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double- blind, randomized trial- the zoledroniñ acid lung cancer and other solid tumors study group / S. Rosen, D. Gordon, S. Tchekmedyian at al. //J Clin Oncol. – 2003. – Vol. 21. – P.3150-3157.
111. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study/ P.D. Ross, B.C. Kress, R.E. Parson at al // Osteoporos Int. – 2000. – Vol. 11. – P. 76- 82.
Rubens, R.D. Bone metastases – the clinical problem / R.D. Rubens // Eur.
112.
J. Cancer. – 1998. – Vol. 34, ¹2. – P.210 - 214.
113. Roodman, G. D. Biology of Osteoclast Activation in Cancer / D. Roodman // Journal of Clinical Oncolog/. – 2001. - Vol. 19. – P. 3562-3571.
114. Roodman, G. D. Mechanisms of Bone Metastasis / G. D. Roodman // The new england journal medicine. – 2004. – Vol. 350. – Ð.1655-1664.
115. Roodman, G. D. Genes associate with abronormal bone cell activity in bone metastasis / G. D. Roodman // Cancer Metastasis Rev. – 2012. – Vol. 10. – P. 1055-1112.
116. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology / G.P. Schmidt.H, Kramer. M.F, Reiser et al. // Top. Magn. Reson. Imaging. – 2007. – Vol. 18, ¹ 3. – P. 193-202.
Long-term variability of bone turnover markers in patients with non – 117.
metastatic breast cancer/ M.J. Seibel, M. Koeller, B. Van Der Velden, I. Diel // Clin Lab. – 2002. –Vol. 48, ¹ 11. – P. 579-582.
118. Markers of bone turnover do not predict bone metastases in breast cancer/
M.J. Seibel, M. Koeller, B. Van Der Velden, I. Die// Clin Lab. – 2002. – Vol. 48:
– P. 583-588.
Biochemical markers of bone turnover: Ðart II:
119. Seibel, M. J. clinical applications in the management of osteoporosis / M. J. Seibel // Ñlin. Biochem Rev. – 2006. –V 26, ¹ 4. –P. 97 – 122.
120. Seibel, M.J. The use of molerular markers of bone turnover in the management of patients with metastatic bone disease/ M.J. Seibel // Clin. Endoc.
–2008. – Vol.68. – P. 839 -849.
121. Bone metastasis: mechanisms and therapeutic opportunities / L.J. Suva, C.
Washan, R. W. Nicolas at al. // Nat. Rev. Endocrinol. – 2011. –Vol. 7, ¹ 4. –P.
208 -2018.
122. Clinical significance of the serum cross- linked N-telopeptide of type I collagen as a prognostic marker for non- small–cell lung cancer / M. Tamiya, H.
Suzuki, M. Kobayashi at al. // Clin. Lung Cancer. – 2013. –Vol. 14. –P. 50 – 54.
123. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients / C.
Tang, Y. Liu, B. Wu et al. // Clin Chim Acta. – 2013. – Vol. 426. – P. 102-107.
124. Taube, T. Tumor invasion to bone. Histomorphometric analysis of bone disease induced by myelomatosis, breast cancer and prostate cancer/ T. Taube // Helsinki. – 2000. – 81p.
Tartrate – resistant acid phosphatase (TRAP) as a serum marker for bone 125.
resorption in breast cancer patients with bone metastases/ S Tauchert, A. Liberto, T. Cordes at al.// Clin Exp Obstet Gynecol. –2009. –Vol. 36, ¹ 4. – P 219 - 225.
126. Urinary pyridinoline and deoxy pyridinoline as potential markers of bone metastasis in patients with prostate cancer/ S. Takeuchi, K. Arai, H. Saitoh at al.// World J Urol. –2007. – Vol. 25. – P. 393-399.
127. Predictors of fractures in fractures in eiderly women/ A.M. Tromp, M.E.
Oms, Ñ. Popp – Shijders, J.C. Roos, P. Lips // Osteoporos Int. – 2000. –Vol.11. – P. 134 - 140.
128. Alkaline phosphatase as indicator of bone formation/ Lips // V.O. Van Hoof, A.T. Van Oosterom, L.G. Lepoute, M. E de Broe / / Osteoporos Int. – 2000. – Vol.11– P. 134 - 140.
129. Increased Dickkropf -1expression in breast cancer bone metastases/ N.
Voorzanger – Rousselot, D. Goehrig, F. Journe at al. // Br J Cancer. – 2007. –V.
97, ¹7. –P. 964 – 970.
130. Relationships between biochemical and symptomatic response in doubleblind randomized trial of pamidronate for metastatic bone disease / J.J/ Vinholes, O.P. Purohit, M.E. Abbey et al. // Ann. Oncol. – 1997. –Vol. 8. –P. 1243– 1250.
131. Evaluation of bone metabolic markers in breast cancer with bone metastasis / N. Wada, M. Fujisaki, T. Ireda, M. Kitajima// Breast Cancer. –2001.
–P. 131-137.
132. Measurement of urinary collagen cross- links indicate response to therapy in patients with breast cancer and bone metastases /J. Walls, A. Assiri, A. howell et all //Br J Cancer 80 – 1999. – Ð.1265-1270.
133. Weber, K.L. Management of osseous metastases and impending pathologic fractures/ K.L. Weber, R.L. Theriault //– 2008. –Vol. 58. – P 579-591.
134. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices/ H.W. Woite et al//J Bone Miner Res.1999. –Vol. 14. –P. 792 – 801.
135. Yamabuki,Ò. Dikkopf-1 as a Novel Serologic and Prognostic Biomarker for Lung and Esophageal Carcinomas / Ò.Yamabuki, À.Takano, S. // Cancer Research – 2007. – Vol. 67 – Ð. 2517-2525.
136. Yang, S.K. The role of PET/CT for evaluating breast cancer / S.K. Yang, N. Cho, W.K. Moon. // Korean J. Radiol. – 2007. – Vol. 8, ¹ 5. – P. 429-237.
137. Yasuda, H. Osteoclast differentiation factor is a li-gand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to Transe /Rankl/ H. Yasuda, N.Shim, N. Nakagawa // Proc Natl Acad Sci. US A. – 1998.
–Vol.95. – P. 3597-3602.
138. Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study / M.H. Yilmaz, M. Ozguroglu, D. Mert et al. // Med Oncol. – 2007. – Vol. 17, ¹1. – P.70-74.
139. Yin, J.J. Mechanisms of cancer metastasis to the bone/ J.J. Yin, C.B.
Pollock, K. Kelly // Cell. Res. – 2005. – Vol.15. – P. 5 - 62.
Elevated serum levels of type collagen degradation marker CTP and 140.
tissue inhibitor of metalloproteinase (TIMP) are associated with poor prognosis in lung cancer / S. Ylisirnio, M. Hoyhtya, R.Makitaro at al. // Ñlin. Ñancer Res. – 2001. – Vol.7. – P. 1633 - 1637.
141. Yoneda, T. Osteolytic bone disease in breast cancer/ T. Yoneda, A. Sasaki, G.R Mundy // Breast Cancer Res. Treat. –1994. –Vol. 32. –P. 73- 84.
142. Laboratory evaluation of bone marrow metastasis: single institute study / H.K. Yun, MG. Shin, W. da Kim et al. // Korean Journal Lab Med. – 2007. – Vol.
27, ¹2. – P. 96-101.
143. Prognostis and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid /X.Zhao, X. Xu, Q. Zhang, J at al. // Bio Med Central. –2011. – Vol.11. – P.403-405.
144. Changes of bone resorption marker Ntx in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases/Y-Y. Zhao, G. Hou, H. Liao et al. // European J of Cancer. –2011. – Vol. 47. – P. 848- 853.
145. Value of C- telopeptide- cross- linred type I collagen, osteocalcin, bonespecific alkaline phosphatase and procollagen type I N- terminal propeptide in diagnosis and prognosis of bone metastasis in patients with malignant tumors/ H.
Zhao, K. Han, Z.Wang, at al. // Med Monit. – 2011. – Vol.17, ¹11. – P 626Diagnostic value of bone metabolic markers ICTP and BAP in patients lung cancer with bone metastases/ Y. Xin, B. Han, J. Lou at al // Zhongguo Fei Ai Za Zhi. –2010. – Vol. 13, ¹ 10. – P. 947-953.
147. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients/ A. Zissimopoulos, D.
Matthaios, E. Matthaiou at al. //J Buon. –2007. – Vol. 12, ¹ 4. – P 505-511.
«